23. (Once amended) A method of delivering a drug to a patient in need thereof, ~~comprising~~

administering a therapeutically or prophylactically effective amount of the drug in a formulation comprising a porous matrix [formed of] which comprises a wetting agent and microparticles of the drug, wherein the microparticles have a mean diameter between about 0.1 and 5 μm and a total surface area greater than about 0.5 m^2/mL, and wherein the [dry] porous matrix [is in a dry powder form having] has a TAP density less than or equal to 1.0 g/mL and/or [having] has a total surface area of greater than or equal to 0.2 m^2/g and is in the form of a dry powder.

25. (Once amended) The method of claim 24 wherein the parenteral route is selected from the group consisting of [intraveneous,] intravenous, intraarterial, intracardiac, intrathecal, intraosseous, intraarticular, intrasynovial, intracutaneous, subcutaneous, and intramuscular administration.

32. (Once amended) The method of claim 23 wherein the formulation is [a dry powder] suitable for pulmonary administration.

Please add the following new claims:

--33. The method of claim 23 wherein the dry powder form of the porous matrix has a TAP density less than or equal to 1.0 g/mL.--

--34. The method of claim 23 wherein the dry powder form of the porous matrix has a total surface area of greater than or equal to 0.2 m^2/g.--